7.28 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||7.22 x 800|
|Ask||7.90 x 800|
|Day's Range||7.07 - 7.54|
|52 Week Range||5.66 - 30.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.00|
Jim Cramer says there are a lot of things that scare him about a U.S.-China trade war, but selling its position in U.S. Treasurys isn’t one of them.
Investors are always looking for growth in small-cap stocks like OptiNose, Inc. (NASDAQ:OPTN), with a market cap of US$248m. However, an important fact which most ignore is: how financially healthy Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® in the United States, Canada, and Mexico. Upon termination of the license agreement, Optinose may elect to continue to commercialize ONZETRA XSAIL itself or through a new licensee. “Optinose intends to evaluate its options with respect to the future of ONZETRA XSAIL,” stated CEO Peter Miller.
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2018 Prescriptions for Success Healthcare Conference on December 12, 2018, at 11:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event.
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
OptiNose (OPTN) delivered earnings and revenue surprises of 10.29% and 21.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Yardley, Pennsylvania-based company said it had a loss of 61 cents per share. The specialty pharmaceutical company posted revenue of $1.9 million in the period. OptiNose shares have decreased 45 percent ...
Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to October Conference call and webcast to.
Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2018, before market open on Tuesday, November 13, 2018. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.
NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of OptiNose, Inc. (“OptiNose” or “the Company”) (NASDAQ: OPTN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Holzer & Holzer, LLC is investigating whether OptiNose, Inc. complied with the federal securities laws. On August 14, 2018, OptiNose issued financial results for the quarter ended June 30, 2018 and reported a net loss of $24.6 million.
The Yardley, Pennsylvania-based company said it had a loss of 64 cents per share. The specialty pharmaceutical company posted revenue of $1.3 million in the period. OptiNose shares have increased 3 percent ...
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / OptiNose, Inc. (NASDAQ: OPTN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:00 AM Eastern Time. To ...
Chart readers and technical analysts do not have a lot of trading history to work with but we can make some thoughtful observations and recommendations. OptiNose is a maker of products for ear, nose and throat conditions, so let's clear our throats and dive into the charts. In this daily bar chart of OPTN, below, we can see a mixed picture with respect to the price action and indicators.